| Name | Title | Contact Details |
|---|
Connections Health Solutions, LLC is the pioneer of behavioral health crisis care. The Company operates the two largest behavioral health crisis facilities in the nation and provides a range of services to help stabilize and treat people with mental health and substance use diagnoses. Connections` model emphasizes providing treatment in the least restrictive setting and has demonstrated improved quality and cost savings, including significantly reducing hospital admissions in Medicaid and behavioral health populations. For more information and crisis resources, please visit www.connectionshs.com. We believe that people do best when they don`t have to wait a long time to get what they need. As a result, we have created a culture in which we welcome everyone regardless of clinical complexity, provide intervention as quickly as possible, and partner with community support systems to maximize recovery. Our corporate mission is simple: to address any behavioral health need, at any time.
All's Well Health Care Services is a Huntington Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
World Product Centre is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are experts in the field, along the sidelines and in locker rooms. We have Richmond's only outdoor assessment field used for testing athletes in simulated game conditions with dedicated areas for soccer, basketball, tennis, track, plus a pitcher's
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.